Cardiovascular Drugs Practice Questions

Q: All the following agents may be used for the management of hypertensive crisis EXCEPT?

Indapamide. ### Explanation The management of a **hypertensive crisis** (Urgency or Emergency) requires rapidly acting, intravenous medications to achieve controlled reduction of blood pressure. **Why Indapamide is the Correct Answer:** Indapamide is a **thiazide-like diuretic** administered exclusively via the **oral route**. It has a slow onset of action and a prolonged duration, making it suitable for the long-term maintenance treatment of essential hypertension, but entirely **ineffective and inappropriate** for the acute, rapid stabilization required in a hypertensive crisis. **Analysis of Incorrect Options:** * **Furosemide (Option A):** A potent loop diuretic that can be given IV. It is specifically indicated in hypertensive emergencies complicated by **acute heart failure or pulmonary edema** to reduce fluid overload. * **Nitroglycerin (Option B):** A venodilator (and coronary vasodilator) given as a continuous IV infusion. It is the drug of choice for hypertensive crises associated with **acute coronary syndrome (ACS)** or acute heart failure. * **Esmolol (Option D):** An ultra-short-acting, cardioselective **beta-blocker** given IV. Due to its rapid onset and very short half-life (~9 minutes), it is ideal for managing hypertension associated with **aortic dissection** or perioperative settings. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** **Sodium Nitroprusside** was traditionally the DOC, but **Labetalol** or **Nicardipine** are now preferred due to better safety profiles. * **Aortic Dissection:** Use Esmolol or Labetalol (Goal: SBP <120 mmHg within 20 mins). * **Pheochromocytoma:** Use Phentolamine (Alpha-blocker). * **Neurological Crisis:** Avoid rapid BP drops to prevent cerebral ischemia; aim for a 20-25% reduction in the first hour.

Q: The side effect of corneal microdeposits is seen most commonly with which of the following drugs?

Amiodarone. **Explanation:** **Amiodarone** is a Class III antiarrhythmic drug known for its extensive side-effect profile due to its high lipid solubility and long half-life. **Corneal microdeposits** (also known as *vortex keratopathy* or *cornea verticillata*) occur in nearly **90-100% of patients** on long-term amiodarone therapy. These deposits are yellowish-brown, bilateral, and located in the basal epithelium. While they are a hallmark side effect, they are usually asymptomatic and rarely necessitate drug discontinuation. **Analysis of Options:** * **A. Esmolol:** An ultra-short-acting cardioselective Beta-1 blocker used for acute supraventricular arrhythmias. Its primary side effect is hypotension; it has no ocular toxicity. * **C. Adenosine:** A drug of choice for Paroxysmal Supraventricular Tachycardia (PSVT). It has an extremely short half-life (<10 seconds) and causes transient side effects like flushing, chest pain, and dyspnea. * **D. Bretylium:** An older Class III agent used for refractory ventricular fibrillation. Its main side effect is orthostatic hypotension. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Amiodarone blocks K+ channels (primary), but also Na+, Ca2+ channels, and alpha/beta-adrenergic receptors. * **Ocular Effects:** Besides corneal deposits, it can rarely cause **Optic Neuritis**, which requires immediate drug cessation. * **Other Key Side Effects:** * **Pulmonary:** Pulmonary fibrosis (most serious). * **Thyroid:** Hypothyroidism or Hyperthyroidism (due to high iodine content). * **Skin:** Blue-gray skin discoloration (Smurf skin). * **Liver:** Elevated transaminases/Hepatotoxicity. * **Monitoring:** Baseline and periodic Chest X-ray, PFTs, Thyroid Function Tests (TFTs), and LFTs are essential.

Q: Ticagrelor is used for what purpose?

Prevention of thrombotic events. **Explanation:** **Ticagrelor** is a potent, direct-acting, and reversible **P2Y12 receptor antagonist**. It belongs to the cyclopentyl-triazolo-pyrimidine class of antiplatelet drugs. By inhibiting the P2Y12 subtype of ADP receptors on the platelet surface, it prevents ADP-mediated activation of the GPIIb/IIIa receptor complex, thereby inhibiting platelet aggregation. **Why Option B is Correct:** The primary clinical indication for Ticagrelor is the **prevention of thrombotic events** (such as myocardial infarction or stroke) in patients with **Acute Coronary Syndrome (ACS)** or those undergoing Percutaneous Coronary Intervention (PCI). Unlike Clopidogrel, Ticagrelor is not a prodrug and does not require metabolic activation, leading to a faster onset and more predictable antiplatelet effect. **Why Other Options are Incorrect:** * **Option A:** Ticagrelor is actually associated with **dyspnea** as a common side effect (due to inhibition of adenosine reuptake). Therefore, it is used with caution in patients with COPD or asthma, rather than as a treatment. * **Option C:** It has no mechanism of action involving systemic vascular resistance or cardiac output to qualify as an antihypertensive. * **Option D:** There is no clinical evidence or pharmacological basis for its use in obesity management. **High-Yield Clinical Pearls for NEET-PG:** * **Reversibility:** Unlike Clopidogrel and Prasugrel (which are irreversible), Ticagrelor binds **reversibly**. * **Metabolism:** It does not require hepatic CYP2C19 activation (important for patients with Clopidogrel resistance). * **Side Effects:** Watch for **dyspnea** and **ventricular pauses/bradycardia**. It can also cause asymptomatic increases in **uric acid** levels. * **PLATO Trial:** This landmark trial established Ticagrelor’s superiority over Clopidogrel in reducing cardiovascular death in ACS patients.

Q: What is the dose of Reteplase for the management of acute myocardial infarction?

10 IU. **Explanation:** **Reteplase** is a second-generation recombinant tissue plasminogen activator (rt-PA). It is a deletion mutant of alteplase with a longer half-life (13–16 minutes), which allows it to be administered as a **bolus injection** rather than a continuous infusion. 1. **Why Option B is Correct:** The standard FDA-approved dosage regimen for Reteplase in acute myocardial infarction (AMI) is a **double-bolus dose of 10 units + 10 units**. Each bolus is administered intravenously over 2 minutes. The second 10-unit bolus is given **30 minutes after the initiation of the first**. This "10 + 10" regimen is designed to provide sustained thrombolytic activity to achieve higher patency rates of the infarct-related artery. 2. **Why Other Options are Incorrect:** * **Option A (5 IU):** This is a sub-therapeutic dose and is not used in standard AMI protocols. * **Option C (15 IU):** While 15 mg is the initial bolus dose for *Alteplase* in the accelerated regimen, it is not the unit-based dose for Reteplase. * **Option D (50 IU):** This dose is excessively high and would lead to a significant risk of life-threatening hemorrhage. (Note: Tenecteplase uses weight-based dosing ranging from 30–50 mg, but not Reteplase). **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Reteplase is relatively non-fibrin specific compared to Alteplase, but it has increased potency and faster onset. * **Administration:** Unlike Alteplase (which requires a 90-minute infusion), Reteplase and Tenecteplase are bolus-only, making them ideal for pre-hospital thrombolysis. * **Comparison:** **Tenecteplase (TNK-tPA)** is the most fibrin-specific and is given as a **single** weight-based bolus, whereas **Reteplase** requires a **double** bolus. * **Monitoring:** Always monitor for the most common side effect: **Bleeding** (specifically intracranial hemorrhage).

Q: What is the drug of choice for pregnancy-induced hypertension?

Alpha-methyldopa. **Explanation:** **Alpha-methyldopa** is the traditional drug of choice for chronic hypertension in pregnancy. It is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow. Its preference in pregnancy stems from its long-standing safety profile and the absence of long-term adverse effects on fetal development or neonatal hemodynamics. **Analysis of Options:** * **Atenolol (Option A):** Beta-blockers, particularly Atenolol, are generally avoided in early pregnancy as they are associated with **fetal growth restriction (IUGR)** and placental complications. * **Nitroprusside (Option B):** It is contraindicated in pregnancy (except in extreme emergencies) due to the risk of **fetal cyanide poisoning**. * **Enalapril (Option C):** ACE inhibitors and ARBs are strictly **contraindicated** in pregnancy. They are teratogenic and can cause fetal renal dysgenesis, oligohydramnios, and skull hypoplasia. **High-Yield Clinical Pearls for NEET-PG:** * **First-line agents:** While Methyldopa is the classic answer, current guidelines (like ACOG) also recommend **Labetalol** (often preferred for its faster onset) and **Nifedipine** (long-acting) as first-line options. * **Acute Hypertensive Crisis in Pregnancy:** The drugs of choice are **IV Labetalol** or **IV Hydralazine**. * **Preeclampsia Prophylaxis:** Low-dose **Aspirin** (started before 16 weeks) is used in high-risk patients. * **Magnesium Sulfate ($MgSO_4$):** This is the drug of choice for preventing and treating seizures in **Eclampsia**, not for blood pressure control.

Q: Which drug prescribed by the physician would most probably be responsible for this condition?

Amiodarone. ***Amiodarone*** - **Amiodarone-induced pulmonary toxicity** is a well-known adverse effect, presenting with bilateral **pulmonary infiltrates** on chest X-ray and progressive dyspnea. - The drug accumulates in **lung tissue** due to its lipophilic nature and long half-life, causing **inflammatory pneumonitis** and potentially **pulmonary fibrosis**. *Digoxin* - Primarily causes **cardiac toxicity** including arrhythmias, heart block, and **digitalis toxicity** symptoms like nausea and visual disturbances. - Does not cause **pulmonary infiltrates** or lung parenchymal damage as its main mechanism involves **Na+/K+-ATPase inhibition**. *Verapamil* - A **calcium channel blocker** that primarily affects the cardiovascular system, causing **bradycardia**, **hypotension**, and potential **heart block**. - **Pulmonary toxicity** is not a recognized adverse effect of verapamil therapy. *Propranolol* - A **non-selective beta-blocker** that can cause **bronchospasm** in asthmatic patients but does not cause **pulmonary infiltrates**. - Main side effects include **bradycardia**, **hypotension**, and **fatigue**, not parenchymal lung disease.

Q: Which of the following agents is a thrombin receptor antagonist?

Vorapaxar. **Explanation:** **Correct Answer: A. Vorapaxar** Vorapaxar is a first-in-class antiplatelet agent that acts as a competitive antagonist of the **Protease-Activated Receptor-1 (PAR-1)**. PAR-1 is the primary receptor for **thrombin** on human platelets. By blocking this receptor, Vorapaxar inhibits thrombin-induced platelet aggregation without interfering with thrombin's ability to convert fibrinogen to fibrin (thus preserving some aspects of the coagulation cascade). It is used clinically to reduce the risk of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease. **Analysis of Incorrect Options:** * **B. Ticagrelor:** This is a reversible **P2Y12 receptor antagonist**. It prevents ADP-mediated platelet activation. Unlike Clopidogrel, it is not a prodrug. * **C. Tirofiban:** This is a **Glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor**. It prevents the final common pathway of platelet aggregation by blocking the binding of fibrinogen to platelets. * **D. Terutroban:** This is a selective **Thromboxane (TP) receptor antagonist**. It blocks the effects of Thromboxane A2 but does not inhibit its synthesis (unlike Aspirin). **High-Yield NEET-PG Pearls:** * **Vorapaxar** has a very long half-life (approx. 3-4 days), making its effects essentially irreversible in clinical practice. * **Contraindication:** It is strictly contraindicated in patients with a history of stroke, TIA, or intracranial hemorrhage due to a significantly increased risk of bleeding. * **Mechanism Summary:** * Aspirin → COX-1 inhibitor. * Clopidogrel/Prasugrel/Ticagrelor → P2Y12 inhibitors. * Abciximab/Eptifibatide/Tirofiban → GP IIb/IIIa inhibitors. * **Vorapaxar → PAR-1 (Thrombin receptor) antagonist.**

Q: Enhancement of the effects of bradykinin is most likely to occur with which of the following drugs?

Lisinopril. **Explanation:** The correct answer is **Lisinopril**. **1. Mechanism of Action (Why Lisinopril is correct):** Lisinopril is an **ACE Inhibitor (ACEI)**. The Angiotensin-Converting Enzyme (ACE) is identical to **Kininase II**, the enzyme responsible for the degradation of bradykinin into inactive peptides. By inhibiting ACE, these drugs prevent the breakdown of bradykinin, leading to its accumulation in the tissues and blood. Increased bradykinin levels contribute to vasodilation but are also responsible for the classic side effects of ACEIs, such as a dry cough and angioedema. **2. Analysis of Incorrect Options:** * **Clonidine:** An alpha-2 adrenergic agonist that acts centrally to reduce sympathetic outflow. It has no effect on the kinin system. * **Diazoxide:** A potassium channel opener used in hypertensive emergencies and insulinomas. It acts directly on vascular smooth muscle and does not involve bradykinin. * **Losartan:** An **Angiotensin Receptor Blocker (ARB)**. Unlike ACEIs, ARBs block the $AT_1$ receptor directly and do not inhibit Kininase II. Therefore, they do not increase bradykinin levels, making them the preferred alternative for patients who develop a cough on ACEIs. **3. NEET-PG High-Yield Pearls:** * **The "Cough" Connection:** The accumulation of bradykinin and substance P in the lungs is the primary cause of the dry, non-productive cough seen in ~10-15% of patients on ACEIs. * **Angioedema:** This is a rare but life-threatening side effect also mediated by excessive bradykinin levels. * **Dual Benefit:** While bradykinin causes side effects, it also contributes to the antihypertensive efficacy of ACEIs by stimulating the release of nitric oxide and prostacyclin ($PGI_2$).

Q: What is the most significant adverse effect of ACE inhibition?

Hypotension. **Explanation:** **ACE inhibitors (ACEIs)**, such as Enalapril and Lisinopril, work by inhibiting the Angiotensin-Converting Enzyme. This prevents the conversion of Angiotensin I to Angiotensin II, a potent vasoconstrictor. By reducing Angiotensin II levels, these drugs cause systemic vasodilation and decrease aldosterone secretion, leading to a reduction in blood pressure. **Why Option A is Correct:** **Hypotension** is the most significant and common acute adverse effect, particularly the **"First-Dose Hypotension."** This occurs due to a sudden withdrawal of the vasoconstrictor influence of Angiotensin II. It is most pronounced in patients with high plasma renin levels, such as those on diuretics or those with congestive heart failure. **Why Other Options are Incorrect:** * **B. Hypertension:** This is the opposite of the intended therapeutic effect. ACEIs are primary antihypertensive agents. * **C & D. Hypo/Hypercalcemia:** ACE inhibitors do not significantly impact calcium metabolism. Their primary electrolyte effect is **Hyperkalemia** (due to decreased aldosterone, leading to potassium retention), which is a high-yield distinction for exams. **NEET-PG High-Yield Pearls:** 1. **Dry Cough:** The most common reason for switching from an ACEI to an ARB (due to increased Bradykinin levels). 2. **Angioedema:** A rare but life-threatening side effect also linked to Bradykinin. 3. **Teratogenicity:** ACEIs are contraindicated in pregnancy as they cause fetal renal anomalies (Potter sequence). 4. **Bilateral Renal Artery Stenosis:** ACEIs are strictly contraindicated here as they can precipitate acute renal failure by reducing efferent arteriolar tone.

Question 1

All the following agents may be used for the management of hypertensive crisis EXCEPT?

Accepted Answer

Indapamide

Answer

Furosemide

Answer

Nitroglycerin

Answer

Esmolol

Question 2

All are true about ranolazine except?

Accepted Answer

It causes hypotension

Answer

It is recommended as first-line treatment for angina

Answer

It improves glycemic control

Answer

It is not indicated for acute attack of angina

Question 3

The side effect of corneal microdeposits is seen most commonly with which of the following drugs?

Accepted Answer

Amiodarone

Answer

Esmolol

Answer

Adenosine

Answer

Bretylium

Question 4

Ticagrelor is used for what purpose?

Accepted Answer

Prevention of thrombotic events

Answer

In COPD patients

Answer

As an antihypertensive

Answer

For weight loss in childhood obesity

Question 5

What is the dose of Reteplase for the management of acute myocardial infarction?

Accepted Answer

10 IU

Answer

5 IU

Answer

15 IU

Answer

50 IU

Question 6

What is the drug of choice for pregnancy-induced hypertension?

Accepted Answer

Alpha-methyldopa

Answer

Atenolol

Answer

Nitroprusside

Answer

Enalapril

Question 7

Which drug prescribed by the physician would most probably be responsible for this condition?

Accepted Answer

Amiodarone

Answer

Digoxin

Answer

Verapamil

Answer

Propranolol

Question 8

Which of the following agents is a thrombin receptor antagonist?

Accepted Answer

Vorapaxar

Answer

Ticagrelor

Answer

Tirofiban

Answer

Terutroban

Question 9

Enhancement of the effects of bradykinin is most likely to occur with which of the following drugs?

Accepted Answer

Lisinopril

Answer

Clonidine

Answer

Diazoxide

Answer

Losartan

Question 10

What is the most significant adverse effect of ACE inhibition?

Accepted Answer

Hypotension

Answer

Hypertension

Answer

Hypocalcemia

Answer

Hypercalcemia

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?